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Editors: Anton N. Sidawy and Bruce A. PerlerEarly results of a multicenter, prospective trial of thoracic
endovascular aortic repair for blunt thoracic aortic injury
(RESCUE trial)
Ali Khoynezhad, Ali Azizzadeh, Carlos E. Donayre, Alan
Matsumoto, Omaida Velazquez, Rodney White
* The Clinical PeRformancE of the Valiant Thoracic Stent
Graft with the Captivia Delivery System for the EndovaS-
CUlar trEatment of Blunt Thoracic Aortic Injuries. A
complete list of the RESCUE investigators can be found in
the Appendix (online only).
Objective: To evaluate the early outcomes of patients
undergoing thoracic endovascular aortic repair for blunt
thoracic aortic injuries.
Methods: A prospective, nonrandomized, multicenter trial
using the Medtronic Valiant Captivia stent graft was con-
ducted at 20 sites in North America. Fifty patients with blunt
thoracic aortic injuries were enrolled between April 2010 and
January 2012 and will be followed for 5 years. The injuries
were classiﬁed into categories (grades I-IV) based on severity:
intimal tear, intramural hematoma, pseudoaneurysm, or
rupture. The primary end point was 30-day all-cause
mortality. Secondary end points were adverse events occur-
ringwithin 30 days that were related to the procedure, device
or aorta, and aortic-related mortality. Technical success was
measured as successful device delivery and deployment.
Results: Seventy-six percent (38/50) of patients were male
with mean age of 41  17 years. Fifty-one Medtronic
Valiant Captivia thoracic stent grafts and a single Talent
thoracic stent graft were implanted within a median of 1.0
day following injury (mean, 1.8 4.0 days). Seventy percent
(35/50) of aortic injuries were grade III or higher, including
one patient with free rupture. Mean injury severity score
was 38  14. Fifty-four percent of stent grafts were 26
mm (28/52). The left subclavian artery was completely
covered in 40% of patients (20/50) and partially covered in
18% of patients (9/50). Four patients underwent subclavian
artery revascularization: one at the time of the endograft
procedure and three others after developing arm ischemia
after the initial endograft procedure. Cerebral spinal ﬂuid
was drained in two patients. The median procedure time
was 91 minutes, and median hospital stay was 12 days.
There was 100% successful device delivery and deployment.
Four (8%) patients died within 30 days. Nonfatal adverse
events within 30 days that were related to the procedure,
device, or aorta were experienced by 12% (6/50) of*Full articles available online at www.jvascsurg.org
1078-5884/$ e see front matter
http://dx.doi.org/10.1016/S1078-5884(13)00159-7patients. No nonfatal adverse events related to the device
were reported; a single death was conservatively adjudi-
cated as device-, procedure-, and aorta-related because of
insufﬁcient information. No patient developed spinal cord
injury, and there were no cerebrovascular accidents.
However, one patient had an anoxic brain injury following
aortic rupture. No patient underwent conversion to open
repair or required an endovascular reintervention.
Conclusions: Based on the early outcomes, the Medtronic
Valiant Captivia stent graft appears to be a promising
treatment modality for blunt thoracic aortic injuries. Long-
term follow-up is necessary to substantiate the effective-
ness of thoracic endovascular aortic repair in treatment of
blunt thoracic aortic injuries.First-in-human study of the INCRAFT endograft in patients
with infrarenal abdominal aortic aneurysms: The
INNOVATION trial
Dierk Scheinert, Carlo Pratesi, Roberto Chiesa, Gioachino
Coppi, Jan S. Brunkwall, Gijs Klarenbeek, Ana Cebrian,
Giovanni Torsello
Objective: This multicenter, prospective, nonrandomized
trial was undertaken to evaluate the ﬁrst-in-human experi-
ence with the INCRAFT endograft (Cordis Corporation,
Bridgewater, NJ), an ultralow-proﬁle trimodular bifurcate
device for the repair of abdominal aortic aneurysms.
Methods: Patients with asymptomatic infrarenal abdominal
aortic aneurysms were eligible for enrollment in the trial.
Anatomic eligibility criteria included a proximal aortic neck
at least 15 mm in length and up to 27 mm in diameter, and
an aortic bifurcation 18 mm in diameter. Iliofemoral
access vessels were required to be large enough to accept
the 14F (4.7 mm) outer diameter of the delivery system. The
primary efﬁcacy end point was technical success, deﬁned by
successful device deployment during the conclusion of the
procedure at the desired location without a type I, III, or IV
endoleak. The primary safety end point was deﬁned by the
absence of a type I, III, or IV endoleak or a device- or
procedure-related major adverse event at the 1-month
follow-up point.
Results: Over a 16-month period divided into two different
phases, 57 men and three women with a mean age of
74.4  6.9 years were enrolled at three German and three
Italian centers. A percutaneous approach was used in 36
patients (60%). Successful graft deployment at the desired
location was achieved in 59 patients (98%). A single patient
had successful deployment of the device although it was
Abstracts 407located more distally than planned. Technical success was
achieved in 54 patients (90%); one patient had a type I
endoleak, four had type IV endoleaks, and one had an
endoleak of undetermined origin. The primary safety end
point was met in 56 of the 58 patients (97%) with complete
core laboratory data at 1 month; two patients had type I
endoleaks. There were no type III or IV endoleaks and no
device or procedure-related major adverse events at 1
month. No limb thromboses or stent fractures were noted
on postoperative imaging studies and no patient required
rehospitalization, a secondary procedure, or open surgical
conversion through 1 month of follow-up.
Conclusions: The INCRAFT endograft device holds promise
as an innovative alternative to currently marketed devices
and broadens the eligibility for endovascular aneurysm
repair. More deﬁnitive observations will be generated as
longer-term data from this trial become available.Delayed volume resuscitation during initial management
of ruptured abdominal aortic aneurysm
Florian Dick, Gabor Erdoes, Philipp Opfermann, Balthasar
Eberle, Juerg Schmidli, Regula S. von Allmen
Objective: In acute traumatic bleeding, permissive arterial
hypotension with delayed volume resuscitation is an
established lifesaving concept as abridge to surgical control.
This study investigated whether preoperatively adminis-
tered volume also correlated inversely with survival after
ruptured abdominal aortic aneurysm (rAAA).
Methods: This retrospective study analyzed prospectively
collected and validated data of a consecutive cohort of
patients with rAAAs (January 2001 to December 2010).
Generally, ﬂuid resuscitation was guided clinically by the
patient’s blood pressure and consciousness. All intravenous
ﬂuids (crystalloids, colloids, and blood products) adminis-
tered before aortic clamping or endovascular sealing were
abstracted from paramedic and anesthesia documentation
and normalized to speed of administration (liters per hour).
Logistic regression modeling, adjusted for suspected con-
founding covariates, was used to investigate whether total
volume was independently associated with risk of death
within 30 days of rAAA repair.
Results: A total of 248 patients with rAAAs were analyzed,
of whom 237 (96%) underwent open repair. A median of
0.91 L of total volume per hour (interquartile range, 0.54-
1.50 L/h) had been administered preoperatively to these
patients. The postoperative 30-day mortality rate was 15.3%
(38 deaths). The preoperative rate of ﬂuid infusion corre-
lated with 30-day mortality after adjustment for con-
founding factors, and the association persisted robustly
through sensitivity analyses: each additional liter per hour
increased the odds of perioperative death by 1.57-fold (95%
conﬁdence interval, 1.06-2.33; P ¼ .026).
Conclusions: Aggressive volume resuscitation of patients
with rAAAs before proximal aortic control predicted an
increased perioperative risk of death, which was indepen-
dent of systolic blood pressure. Therefore, volumeresuscitation should be delayed until surgical control of
bleeding is achieved.Predictive factors of 30-day unplanned readmission after
lower extremity bypass
James T. McPhee, Neal R. Barshes, Karen J. Ho, Arin
Madenci, C. Keith Ozaki, Louis L. Nguyen, Michael Belkin
Background: Thirty-day unplanned readmission after lower
extremity bypass represents a large cost burden and is
a logical target for cost-containment strategies. We under-
took this study to evaluate factors associated with
unplanned readmission after lower extremity bypass.
Methods: This is a retrospective analysis from a prospective
institutional registry. All lower extremity bypasses for
occlusive disease from January 1995 to July 2011 were
included. The primary endpoint was 30-day unplanned
readmission. Secondary endpoints included graft patency
and limb salvage.
Results: Of 1543 lower extremity bypasses performed,
84.5% were for critical limb ischemia and 15.5% were
patients with intermittent claudication. Twenty-seven
patients (1.7%) died in-house and were excluded from
further analysis. Of 1516 lower extremity bypasses
analyzed, 42 (2.8%) were in patients with a planned read-
mission within 30 days, and 349 (23.0%), in patients with an
unplanned readmission. Most unplanned readmissions
were wound related (62.9%). By multivariable analysis,
preoperative predictive factors for unplanned readmission
were dialysis dependence (odds ratio [OR], 1.73; P ¼ .004),
tissue loss indication (OR, 1.62; P ¼ .0004), and history of
congestive heart failure (OR, 1.43; P ¼ .03). Postoperative
predictors included distal inﬂow source (OR, 1.38; P ¼ .016),
in-hospital wound infection (OR, 8.30; P < .0001), in-
hospital graft failure (OR, 3.20; P < .0001), and myocardial
infarction (OR, 1.96; P < .04). Neither index length of stay
nor discharge disposition independently predicted
unplanned readmission. Unplanned readmission was asso-
ciated with loss of assisted primary patency (hazard ratio,
1.39; 95% conﬁdence interval, 1.08-1.80; P ¼ .01) and long-
term limb loss (hazard ratio, 1.68; 95% conﬁdence interval,
1.23-2.29; P ¼ .001).
Conclusions: Thirty-day unplanned readmission is
a frequent occurrence after lower extremity bypass (23.0%).
Stratifying patients by risk factors associated with
unplanned readmission is essential for quality improvement
and equitable resource allocation when disease-speciﬁc
bundling strategies are being derived.Long-term clinical efﬁcacy of endovascular therapy for
patients with critical limb ischemia attributable to pure
isolated infrapopliteal lesions
Osamu Iida, Yoshimitsu Soga, Yasutaka Yamauchi, Keisuke
Hirano, Daizo Kawasaki, Terutoshi Yamaoka, Mitsuyoshi
Takahara, Masaaki Uematsu
408 European Journal of Vascular and Endovascular Surgery Volume 45 Issue 4 April/2013Background: Prognosis of endovascular therapy (EVT) for
isolated infrapopliteal lesions has not been adequately
studied. We investigated and risk-stratiﬁed long-term
prognosis after EVT for critical limb ischemia (CLI) attribut-
able to isolated infrapopliteal lesions.
Methods: Between March 2004 and October 2010, 884
patients (1057 limbs) with CLI attributable to isolated
infrapopliteal lesions who underwent EVT with angioplasty
alone were enrolled. Outcome measures were freedom
from major adverse limb events with perioperative death
(MALEþPOD) and amputation-free survival. Cox propor-
tional hazards models were used to assess independent
predictors for these outcomes.
Results: Freedom from MALEþPOD was 82  1% and 74 
2% at 1 and 5 years, respectively. Risk factors associated
with MALEþPOD were age 80 years (adjusted hazard ratio
[HR], 0.4; P < .001), nonambulatory status (HR, 2.0; P <
.001), albumin <3.0 g/dL (HR, 1.4; P < .0001), Rutherford 6
(HR, 2.2; P < .001), C-reactive protein 3.0 mg/dL (HR, 2.1;
P < .001), and below-the-ankle disease (HR, 2.0; P < .001).
One- and 5-year amputation-free survival was 71  2% and
38  3%, respectively. Risk factors associated with major
amputation/mortality were nonambulatory status (adjusted
HR, 2.1; P < .001), body mass index <18.5 kg/m2 (HR, 1.4;
P ¼ .02), albumin <3.0 g/dL (HR, 1.8; P < .0001), end-stage
renal disease (HR, 1.4; P ¼ .004), ejection fraction <50%
(HR, 1.6; P < .001), Rutherford 6 (HR, 1.9; P < .001), C-
reactive protein 3.0 mg/dL (HR, 1.7; P < .0001), and
below-the-ankle disease (HR, 1.8; P < .001). In patients with
more than four risk factors, both endpoints at 1 year were
below the 71% suggested efﬁcacy objective performance
goal.
Conclusions: Long-term clinical outcomes were acceptable
after EVT for patients with CLI due to pure isolated infra-
popliteal lesion. Risk stratiﬁcation by baseline characteris-
tics is useful in estimating long-term prognosis.Management of limb ischemia in acute proximal aortic
dissection
Kristofer M. Charlton-Ouw, Kaji Sritharan, Samuel S. Leake,
Harleen K. Sandhu, Charles C. Miller, Ali Azizzadeh, Hazim J.
Saﬁ, Anthony L. Estrera
Background: Management of limb and other malperfusion
syndromes is controversial in acute type A aortic dissection.
We assessed our hypothesis that urgent proximal aortic
repair resolves most cases of limb ischemia without addi-
tional peripheral revascularization.
Methods: We retrospectively reviewed operative cases of
acute type A aortic dissection from 1999 to 2011. Our
standard technique involved urgent replacement of the
ascending aorta and hemiarch. Persistent limb ischemia
after aortic repair was treated by bypass surgery. Compar-
isons between groups both with and without limb ischemia
were made.
Results: We repaired 335 cases during the study period.
Sixty-one patients had limb ischemia (18.2%), of whom 51were classiﬁed with lower limb ischemia (15.2%). All
patients with upper limb ischemia survived to discharge
without limb loss or death. Only 11 of the 51 patients with
lower limb ischemia (21.6%) required peripheral revascu-
larization after aortic repair. There was one case of lower
limb loss resulting from delayed recognition of persistent
ischemia. Renal dysfunction occurred in 21% of patients
with isolated lower limb ischemia and in 31% of patients
with uncomplicated dissection (P ¼ .29). In-hospital
mortality was 13.7% overall and 8.0% in patients with iso-
lated lower limb ischemia (P ¼ .89). There was no difference
in long-term survival between isolated limb ischemia and
uncomplicated cases (P ¼ .54).
Conclusions: Most cases of limb ischemia resolve after
immediate repair of acute type A aortic dissection. There is
no difference in renal dysfunction or in-hospital or long-
term mortality between patients with isolated limb
ischemia and those with nonmalperfusion dissection. If
ischemia persists, limb salvage is successful if revasculari-
zation is expeditious.High-resolution magnetic resonance imaging of carotid
atherosclerosis identiﬁes vulnerable carotid plaques
Antoine Millon, Jean-Louis Mathevet, Loic Boussel, Peter L.
Faries, Zahi A. Fayad, Philippe C. Douek, Patrick Feugier
Objective: Carotidmagnetic resonance imaging (MRI)may be
a useful tool in characterizing carotid plaque vulnerability, but
large studies are still lacking.The purpose of this study was to
assess carotid MRI features of vulnerable plaque in a large
study and the changes in carotid plaque morphology with
respect to time since the neurological event.
Methods: We included 161 patients with carotid plaque
more than 3 mm thick. All patients underwent carotid MRI
to obtain 3-T high-resolution magnetic resonance
sequences. Large lipid core, intraplaque hemorrhage (IPH),
ﬁbrous cap rupture (FCR), and gadolinium enhancement
(GE) were assessed and classiﬁed as present or absent.
Prevalences of these features were then compared between
symptomatic and asymptomatic patients and time since
stroke.
Results: Seven patients were excluded because of poor
image quality. Of the remaining 154 patients, 52 were
symptomatic and 102 were asymptomatic. The prevalences
of IPH (39 vs 16%; P ¼ .002), FCR (30 vs 9%; P ¼ .001), and
GE (75 vs 55%; P ¼ .015) were signiﬁcantly higher in
symptomatic than asymptomatic patients. After multivar-
iate analysis, the prevalences of IPH (odds ratio, 2.6; P ¼
.023) and FCR (odds ratio, 2.8; P ¼ .038) were still signiﬁ-
cantly higher. The prevalence of IPH was signiﬁcantly higher
in symptomatic patients with plaque regardless of the time
since the neurological event. For FCR, the difference
between symptomatic and asymptomatic patients was
signiﬁcant only during the ﬁrst 15 days after the neuro-
logical event.
Conclusion: Carotid MRI can identify plaque features that
are associated with symptomatic presentation and may be
Abstracts 409indicative of plaque vulnerability. These features may ulti-
mately be used in the management of extracranial carotid
stenosis.Perioperative and late clinical outcomes of 105
percutaneous transluminal stentings of the celiac and
superior mesenteric arteries over the past decade
Ali F. AbuRahma, John E. Campbell, Patrick A. Stone, Ste-
phen M. Hass, Albeir Y. Mousa, Mohit Srivastava, Aravinda
Nanjundappa, L. Scott Dean, Tammi Keiffer
Background: Several authorities have proposed stenting of
the superior mesenteric artery (SMA)/celiac artery (CA) as
the primary treatment for patients with chronic mesenteric
ischemia. However, most of these reports had small
samples and short follow-up periods.
Methods: Eighty-three patients were treated over a 10-year
period. Clinical follow-up and duplex ultrasound exams
were done to evaluate long-term patency. We used our
newly validated duplex criteria to detect 70% in-stent
stenosis of the SMA and CA. A Kaplan-Meier life-table
analysis was used to estimate freedom from in-stent
stenosis and late symptom and survival rates.
Results: Fifty-four SMA and 51 CA stents were analyzed. The
initial technical and clinical success rates were 97% and
96%, respectively, with 2% procedure morbidity and 2%mortality. The primary late clinical success rate was 59%,
and the late 70% in-stent stenosis rate was 51% at a mean
follow-up of 31 months (range, 1-124). Freedom from late
recurrent symptoms at 1, 2, 3, 4, and 5 years was 83, 77, 70,
70, and 65%, respectively. Survival rates at the same
intervals were 88%, 82%, 70%, 64%, and 51%. Primary
patency rates for the whole series were 69%, 48%, 39%,
28%, and 19% at 1, 2, 3, 4, and 5 years, respectively.
Assisted primary patency rates for the whole series were
80%, 61%, 54%, 43%, and 34% at 1, 2, 3, 4, and 5 years,
respectively. Primary patency rates for the SMA at 1, 2, 3, 4,
and 5 years were 71%, 47%, 37%, 28%, and 18%, respec-
tively; and assisted primary rates were 82%, 64%, 57%, 45%,
and 32%, respectively. Primary patency rates for the CA
were 68%, 50%, 40%, 29%, and 21%; and assisted primary
rates were 79%, 58%, 52%, 42%, and 36% for 1, 2, 3, 4, and
5 years, respectively. There were no signiﬁcant differences
in either primary or assisted primary patency between the
SMA and CA (P ¼ .7729 and .8169). A secondary interven-
tion was carried out in 30% of the series. Freedom from
70% in-stent stenosis for the SMA was 82%, 65%, 56%,
42%, and 34%, and that for the CA was 73%, 59%, 48%,
34%, and 25%, at 1, 2, 3, 4, and 5 years, respectively.
Conclusions: Stenting of SMA/CA stenosis has high tech-
nical/early clinical success rates with a satisfactory late
clinical outcome; however, it is associated with high rates of
late in-stent stenosis and intervention.
